인간 두뇌에서 세로토닌 2A 수용체의 LSD 점유 (dOccLS)
인간 뇌에서 세로토닌 2A 수용체의 Lysergic Acid Diethylamide 점유
The investigators wish to quantify the relation between administered dose of lysergic acid diethylamide (LSD), plasma LSD levels, and occupancy at the serotonin 2A receptor (5-HT2AR) using [11C]CIMBI-36 positron emission tomography.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Healthy participants will be administered one of a single dose of lysergic acid diethylamide (LSD) between 25 and 200 micrograms equivalent freebase. They will receive [11C]CIMBI-36 positron emission tomography (PET) scans at baseline and twice following LSD administration during peak and declining drug effects. PET scans will be acquired in a simultaneous PET/Magnetic Resonance Imaging (MRI) scanner which will also collect functional brain imaging data. Venous blood samples will be repeatedly drawn during acute drug effects for quantification of plasma LSD levels. Participants will also repeatedly rate their subjective drug intensity on a scale from 0 to 10 during acute drug effects. Together these data will inform the dose-binding relation of LSD at the serotonin (5-HT) 2A receptor, the primary site of action. This data will also inform the relation between 5-HT2A receptor binding by LSD and the induced subjective effects, as well as the effects on functional brain activity as measured with functional MRI.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 초기 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Gitte M Knudsen, DMsc, MD
- 전화번호: +45 35456720
- 이메일: gmk@nru.dk
연구 연락처 백업
- 이름: Patrick M Fisher, PhD
- 전화번호: +45 35456714
- 이메일: patrick.fisher@nru.dk
연구 장소
-
-
-
Copenhagen, 덴마크, 2100
- 모병
- Neurobiology Research Unit, Rigshospitalet
-
연락하다:
- Gitte M Knudsen, DMSc
- 전화번호: +45 35456720
- 이메일: gmk@nru.dk
-
부수사관:
- Drummond E. McCulloch, BSc
-
부수사관:
- Patrick M. Fisher, PhD
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
• Healthy individual between 18-75 years old
Exclusion Criteria:
- Current or past history of primary psychiatric illness (The Diagnostic and Statistical Manual of Mental Disorders IV axis-I or World Health Organisation International Classification of Diseases-10 diagnostic classification)
- Current or past history of primary psychiatric illness (The Diagnostic and Statistical Manual of Mental Disorders IV axis-I or World Health Organisation International Classification of Diseases-10 diagnostic classification) in a first degree relative (i.e., parents, siblings)
- Current or past history of neurological disease, significant somatic condition/disease
- Use of medication that could potentially influence results (e.g.., drugs that act on relevant components of the serotonin system or may interfere with metabolism of study drug)
- Non-fluent Danish language skills
- Profound visual or auditory impairments
- Severe learning disability
- Pregnancy on the scan date, verified by a pregnancy test (test omitted if confirmed that individual is post-menopausal)
- Lactation (females)
- Contraindications for magnetic resonance imaging (e.g., pacemaker, claustrophobia, etc.)
- Contraindications for positron emission tomography
- Alcohol or drug abuse
- Allergy to administered compounds
- Participant in research study with >10 millisievert exposure within the past year or significant occupational exposure to radioactive substances
- Abnormal ECG (ECG indicating current or previous heart disease or predisposition to heart disease, e.g., QT prolongation) or use of QT prolonging medication
- Use of psychedelic substance within the preceding six months
- Blood donation up to three months before the study (i.e., more than 500ml of blood)
- Head injury or concussion resulting in loss of consciousness for more than 2 min
- Haemoglobin levels < 7.8 mmol/l for women and 8.4 mmol/l for men
- Ferritin levels outside normal range (12-300 µg/L)
- Body-weight < 50 kg or > 110kg
- body-mass index > 35
- Individual assessment by research staff deeming drug administration unsafe due to ethical or psychological circumstance of the participant
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: LSD dose-ranging group
All participants will receive between 25 and 200 micrograms of lysergic acid diethylamide equivalent as freebase, single blinded with respect to dose. Simultaneous PET/MR imaging will be performed during acute drug effects. |
D-Lysergic Acid Diethylamide (LSD) D-tartrate as oral drinking solution (water / ethanol 20% m/m)
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Plasma LSD - serotonin 2A receptor (5-HT2AR) occupancy relation
기간: Within 24 hours following drug administration
|
Occupancy will be estimated by comparing non-displaceable binding potential (BPND) values using baseline and intervention rescans as calculated using a simplified reference tissue model (SRTM). Occupancy values will be compared to plasma lysergic acid diethylamide (LSD) levels. |
Within 24 hours following drug administration
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Subjective drug intensity - 5-HT2AR occupancy relation
기간: Within 24 hours following drug administration
|
Occupancy will be calculated as described above. Subjective drug intensity is collected during positron emission tomography (PET) scans by asking participants. |
Within 24 hours following drug administration
|
|
fMRI network disintegration - 5-HT2AR occupancy relation
기간: Within 24 hours following drug administration
|
functional magnetic resonance imaging (fMRI) data will be used to estimate functional-network connectivity using a standard functional brain atlas. Then the relation between decreases in functional network connectivity and 5-HT2AR occupancy will be estimated. |
Within 24 hours following drug administration
|
|
fMRI brain entropy - 5-HT2AR occupancy relation
기간: Within 24 hours following drug administration
|
fMRI brain entropy will be estimated by the shannon entropy of dynamic conditional correlation of within and between network connectivity as well as the lempel-ziv complexity of concatenated binarised blood-oxygen level dependent (BOLD) signals across regions. The relation between each of these measures with 5-HT2AR occupancy will be estimated. |
Within 24 hours following drug administration
|
|
Cerebral perfusion - 5-HT2AR occupancy relation
기간: Within 24 hours following drug administration
|
Cerebral perfusion will be estimated using arterial spin labelling. The relation between this measure and 5-HT2AR occupancy will be estimated. |
Within 24 hours following drug administration
|
|
Administered LSD dose - 5-HT2AR occupancy relation
기간: Within 24 hours following drug administration
|
Administered dose (25 to 200 mcg) will be compared with peak LSD occupancy to determine what doses produce maximal occupancy at the 5-HT2AR. |
Within 24 hours following drug administration
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Hysteresis effect of 5-HT2AR binding
기간: Within 24 hours following drug administration
|
Estimated dose-occupancy curves derived from the first PET scan and second PET scan will be calculated separately to evaluate whether there are differences in estimated plasma level-occupancy relation at different timepoints following LSD administration which may indicate a hysteresis effect due to peripheral LSD metabolism without unbinding of LSD from the 5-HT2A receptor. |
Within 24 hours following drug administration
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Gitte M Knudsen, DMsc, MD, Copenhagen University Hospital, Rigshospitalet
간행물 및 유용한 링크
유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- H-21060056
- 2021-002633-42 (EudraCT 번호)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .